Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%

"While we have started to prepare for the launch of pixantrone in 2010 with the recruitment of key commercial personnel and conducting important market research, we remained focused on tight fiscal controls while continuing to clean-up our balance sheet," said James A. Bianco, M.D., CEO of the Company. "We are pleased with our continued financial progress demonstrating a decrease in net loss of 45% for the nine months in 2009 compared to the same period for 2008," noted Dr. Bianco. "With the recent developments and progress we are making in advancing pixantrone through its New Drug Application (NDA) review process we expect the next 3 to 6 months to be an exciting and transformative period for the Company."

Recent Highlights

    --  FDA accepted and filed for review the Company's NDA for pixantrone as
        treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma
        (NHL).
    --  The Company initiated the process of obtaining marketing approval in
        Europe in July 2009, for the treatment of relapsed or refractory
        aggressive NHL.
    --  Further reduced debt through the exchange of $4.5 million principal in
        debt for common stock resulting in a total of $57.4 million principal
        reduction in debt through exchanges so far in 2009.

    --  Added to the NASDAQ OMX Global Biotechnology Index (Nasdaq: QGBI).

For the quarter ended September 30, 2009, total net operating expenses were approximately $27.1 million, compared to $20.5 million for the same period in 2008. Research and development expenses decreased by 33% to $7.6 million compared to $11.3 million for the same period in 2008. Net loss attributable to common shareholders was $48.8 million ($0.09 per share), compared to a net loss attributable to common shareholders of $47.6 million ($2.83 per share) for the same period in 2008. The net loss for the quarter ended September 30, 2009 included the following non-cash expenses: $11.4 million in equity-based compensation expense, $6.0 million in milestone payment modification expense and $13.8 million preferred stock deemed dividend expenses. Combined, these non-cash expenses totaled $31.2 million. The modification to the milestone expense relates to the agreement to issue $6.0 million of shares of the Company's common stock to Systems Medicine, Inc. shareholders, which replaced potential milestone payments of up to $15.0 million based certain FDA milestones for the Company's product candidate brostallicin.

For the nine months ended September 30, 2009, total net operating expenses decreased approximately 29% to $55.4 million, compared to $77.5 million for the same periods in 2008. The decrease is mainly a result of a 47% decrease in research and development expenses and a $10.2 million gain on the sale of the Company's remaining interest in a 50/50-owned joint venture with Spectrum Pharmaceuticals, Inc. in 2009. Net loss attributable to shareholders decreased 45% to $89.4 million ($0.21 per share), compared to a net loss attributable to shareholders of $161.6 million ($13.68 per share) for the same period in 2008.

Conference Call Information

On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of CTI's management team will host a quarterly conference call to discuss CTI's 2009 third quarter achievements and financial results.

    Conference Call Numbers
    Thursday, November 5, 2009
    8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
    1-877-941-6010 (US Participants)
    1-480-629-9772 (International)

    Call-back numbers for post-listening available at 11:30 a.m. Eastern:
    1-800-406-7325 (US Participants)
    1-303-590-3030 (International)
    Passcode: 4168724#

Live audio webcast at www.celltherapeutics.com will be archived for post-call listening approximately two hours after call ends.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of our securities. Specifically, the risks and uncertainties include statements about our ability to continue to reduce our operating expenses, our ability to continue to raise capital as needed to fund our operations, the development of OPAXIO, pixantrone, and brostallicin, which include risks associated with preclinical and clinical developments in the biopharmaceutical industry, in general, and with OPAXIO, pixantrone, and brostallicin, in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma or to achieve market acceptance for such treatments, the possibility that FDA approval is not granted for pixantrone at all, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling OPAXIO, pixantrone, and brostallicin, and the risk factors listed or described from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, we do not intend to update or alter our forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/media.htm

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors.htm

                               Cell Therapeutics, Inc.
                   Condensed Consolidated Statements of Operations
                      (In thousands, except per share amounts)
                                     (unaudited)


                                  Three Months Ended     Nine Months Ended
                                    September 30,          September 30,
                                    -------------          -------------
                                  2009          2008      2009       2008
                                  ----          ----      ----       ----
    Revenues:
      Product sales                 $-        $2,580        $-     $8,824
      License and contract revenue  20            20        60         60
                                   ---           ---       ---        ---
        Total revenues              20         2,600        60      8,884
                                   ---         -----       ---      -----
    Operating expenses, net:
      Cost of product sold           -           692         -      2,349
      Research and
       development               7,602        11,326    22,878     43,038
      Selling, general
       and administrative       19,667         7,834    38,997     30,562
      Amortization of
       purchased intangibles         -           606         -      1,540
      Restructuring charges and
       related gain on sale of
       assets, net                (178)            -     3,766          -
      Gain on sale of investment
       in joint venture              -             -   (10,244)         -
                                   ---           ---   -------        ---
        Total operating
         expenses, net          27,091        20,458    55,397     77,489
                                ------        ------    ------     ------
    Loss from operations       (27,071)      (17,858)  (55,337)   (68,605)
    Other income (expense):
      Investment and
       other income, net            26           146        97        499
      Interest expense            (826)       (2,575)   (4,026)    (6,955)
      Amortization of
       debt discount and
       issuance costs             (227)      (11,113)   (5,575)   (52,259)
      Foreign exchange
       gain                        183         3,070       278        909
      Make-whole
       interest expense              -       (19,135)   (6,345)   (52,512)
      Gain on
       derivative
       liabilities, net              -        12,915     7,218     56,092
      Gain (loss) on
       exchange of
       convertible notes           180       (10,272)    7,381    (15,880)
      Equity loss from
       investment in
       joint venture                 -             -    (1,204)         -
      Milestone
       modification
       expense                  (6,000)            -    (6,000)         -
      Settlement
       expense, net             (1,342)         (799)   (4,710)      (799)
      Write-off of
       financing
       arrangement costs             -             -         -     (2,361)
                                   ---           ---       ---     ------
    Net loss before
     noncontrolling
     interest                  (35,077)      (45,621)  (68,223)  (141,871)
      Noncontrolling
       interest                     53            32       205         95
                                   ---           ---       ---        ---
    Net loss
     attributable to CTI       (35,024)      (45,589)  (68,018)  (141,776)
      Gain on
       restructuring of
       preferred stock               -             -     2,116          -
      Preferred stock
       dividends                     -          (106)      (24)      (574)
      Deemed dividends
       on preferred
       stock                   (13,812)       (1,951)  (23,460)   (19,216)
                               -------        ------   -------    -------
    Net loss
     attributable to CTI
     common shareholders      $(48,836)     $(47,646) $(89,386) $(161,566)
                              ========      ========  ========  =========
    Basic and diluted
     net loss per common
     share                      $(0.09)       $(2.83)   $(0.21)   $(13.68)
                                ======        ======    ======    =======
    Shares used in calculation
     of basic and diluted
     net loss per
     common share              527,204        16,812   420,520     11,807
                               =======        ======   =======     ======


    Balance Sheet Data:     (amounts in thousands)

                              September 30,  December 31,
                                  2009          2008
                                  ----          ----
                              (unaudited)
    Cash and cash
     equivalents and
     securities
     available-for-sale         $54,992       $10,671
    Restricted cash                   -         6,640
    Working capital             (13,385)      (14,141)
    Total assets                 87,299        64,243
    Convertible debt             62,015       142,373
    Accumulated deficit      (1,401,706)   (1,312,320)
    Total deficit               (11,633)     (132,061)

SOURCE Cell Therapeutics, Inc.

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,HEA,MTC,ERN,CCA,WA-Cell-Therapeutics